COPD Management Guideline

Initial Therapy Based on Symptom Severity

The American Thoracic Society recommends that for patients with mild symptoms (GOLD A), short-acting bronchodilators (SABA or SAMA) should be used as needed for symptom relief 3, 1
For patients with more persistent symptoms (GOLD B), the European Respiratory Society suggests long-acting bronchodilator monotherapy (LAMA preferred over LABA) 1, 4
The American College of Chest Physicians recommends that for patients with high exacerbation risk (GOLD C), LAMA monotherapy is preferred due to superior exacerbation prevention compared to LABA 1, 4
For patients with severe symptoms and high exacerbation risk (GOLD D), the Global Initiative for Chronic Obstructive Lung Disease recommends LABA/LAMA combination as initial therapy 1, 4

The American Thoracic Society states that LAMAs significantly improve lung function, reduce dyspnea, enhance quality of life, and reduce exacerbation rates 1, 2
LAMAs have a greater effect on exacerbation reduction compared to LABAs and decrease hospitalizations, according to the American College of Chest Physicians 1
The European Respiratory Society notes that tiotropium improves the effectiveness of pulmonary rehabilitation in increasing exercise performance 1, 2
LABAs significantly improve lung function and symptoms, as recommended by the American Thoracic Society 1

The European Respiratory Society recommends that ICS should be reserved for specific patient groups, not as first-line therapy 3, 5
ICS combined with LABA is recommended for patients with frequent exacerbations despite optimal bronchodilator therapy, according to the Global Initiative for Chronic Obstructive Lung Disease 5, 2
Regular ICS treatment increases the risk of pneumonia, especially in severe disease, as noted by the American College of Chest Physicians 1, 2

The American Thoracic Society states that triple therapy (ICS/LABA/LAMA) improves lung function, symptoms, and health status compared to ICS/LABA or LAMA monotherapy 1
The European Respiratory Society recommends considering triple therapy for patients who develop additional exacerbations on LABA/LAMA therapy 4
Triple therapy is most beneficial in patients with severe COPD and a history of frequent exacerbations, according to the Global Initiative for Chronic Obstructive Lung Disease 3, 4

The European Respiratory Society suggests considering roflumilast (PDE4 inhibitor) for patients with severe COPD, chronic bronchitis, and a history of exacerbations despite optimal therapy 5, 4
Macrolides may be considered as an alternative treatment for patients still experiencing exacerbations despite optimal treatment, as recommended by the American College of Chest Physicians 5
Theophylline exerts a small bronchodilator effect with modest symptomatic benefits, but is generally reserved as a third-line option, according to the American Thoracic Society 1, 5